Visiongate Automates its Cell-CT 3D Imaging System for Early Cancer Diagnosis

US-based Visiongate, specialising in non-invasive testing and early diagnosis of lung cancer has announced that it has completed the automation of its proprietary Cell-CT 3D imaging system which provides high resolution three-dimensional images from healthy cells.

The company was able to achieve this through a $2.6 million grant provided by the Biomedical Research, Development and Growth to spur the Acceleration of New Technologies (BRDG-SPAN Program) of the National Institutes of Health. The company also announced that it will make a presentation at the OneMedForum 2012 Finance Conference to be held on January 10, 2012.

The Cell-CT system from the company is to be used in the LuCED test which is a non-invasive testing for the diagnosis of lung cancer. To begin with, the LuCED test will be marketed with computed tomography scans for the detection of lung cancer in individuals who are at high risk, during the early stages. According to the Chairman and CEO of Visiongate, Alan Nelson it was essential to automate the imaging system in order to cater to large patient populations and ensure faster and accurate diagnosis. He also added that Cell-CT platform will act as a powerful tool for pathologists to be used in various applications. The company will apply to the Food and Drug Administration for the review of LuCED test during the later part of this year. At present around 160,000 Americans are being killed by lung cancer every year. The technology used in the Cell-CT system has been covered by 66 patents all across the world.